Clinical Trials Browser

Has results × Ganglioneuroblastoma × sargramostim × Clear all

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Phase 2 Active not recruiting

41 enrolled 13 charts

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2025-10-09

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 2 Active not recruiting

42 enrolled 12 charts

Ganglioneuroblastoma

NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Phase 2 Completed

73 enrolled 12 charts

Neuroblastoma, Ganglioneuroblastoma